Gabapentin News and Research

RSS
Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Migraine prevention guidelines released

Migraine prevention guidelines released

Impax initiates challenge of patents related to generic Gralise

Impax initiates challenge of patents related to generic Gralise

Positive effect of tafamidis on neurological degeneration

Positive effect of tafamidis on neurological degeneration

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept fourth quarter revenue decreases to $0.2 million

Depomed, Santarus reach agreement to resolve GLUMETZA patent litigation with Lupin

Depomed, Santarus reach agreement to resolve GLUMETZA patent litigation with Lupin

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

Epilepsy community concerned over AHRQ's AED drug comparison study

Epilepsy community concerned over AHRQ's AED drug comparison study

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

Hi-Tech Pharmacal second quarter net sales increase 27% to 56,875,000

Hi-Tech Pharmacal second quarter net sales increase 27% to 56,875,000

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

AAN updated guideline on how to best treat essential tremor

AAN updated guideline on how to best treat essential tremor

NextBio predicts mechanisms underlying drug toxicity and identifies new cancer biomarker

NextBio predicts mechanisms underlying drug toxicity and identifies new cancer biomarker

Hi-Tech Pharmacal first quarter sales increase 43% to $56.2 million

Hi-Tech Pharmacal first quarter sales increase 43% to $56.2 million

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Caffeine can treat postdural puncture headaches

Caffeine can treat postdural puncture headaches

Soy useless for menopause

Soy useless for menopause

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Women & Infants Hospital fellow earns ASCO's Conquer Cancer Foundation award

Women & Infants Hospital fellow earns ASCO's Conquer Cancer Foundation award